ObsEva SA to Participate in September Investor Conferences
28 Agosto 2018 - 12:30AM
ObsEva SA to Participate in September Investor Conferences
Geneva, Switzerland and Boston, MA –
August 28, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a
clinical-stage biopharmaceutical company focused on the development
and commercialization of novel therapeutics for serious conditions
that compromise a woman’s reproductive health and pregnancy, today
announced that Company Management will be participating in the
investor conferences listed below.
- The Rodman & Renshaw 20th Annual Global Investment
Conference taking place in New York September 4-6, 2018. ObsEva
will be presenting on Wednesday September 5, 2018, at 5:05 p.m.
Eastern Time.
- The Baird 2018 Global Healthcare Conference taking place in New
York on September 5-6, 2018. ObsEva will be presenting on Thursday
September 6, 2018, at 10:50 a.m. Eastern Time.
- BioCentury’s 25th Annual NewsMakers in the Biotech Industry
Conference taking place in New York on Friday September 7, 2018.
ObsEva will be presenting on Friday September 7, 2018 at 11:30 a.m.
Eastern Time.
- Investora 6th Swiss Small and Mid-Cap Conference taking place
in Zürich on September 26-27, 2018. ObsEva will be presenting on
Thursday September 27, 2018, at 4.15 p.m. Central Eastern Summer
Time.
Rodman & Renshaw and Baird presentation
webcasts will be available in the “Investors” section of ObsEva’s
website www.ObsEva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical
company focused on the clinical development and commercialization
of novel therapeutics for serious conditions that compromise a
woman's reproductive health and pregnancy. Through strategic
in-licensing and disciplined drug development, ObsEva has
established a late-stage clinical pipeline with development
programs focused on treating endometriosis, uterine fibroids,
preterm labor and improving IVF outcomes. ObsEva is listed on the
NASDAQ Global Select Market and is trading under the ticker symbol
"OBSV" and on the SIX Swiss Exchange where it is trading under the
ticker symbol “OBSN”.
For more information, please visit
www.ObsEva.com.
###
For further information, please
contact:
Media Contact Switzerland and
Europe:Christophe LampsDynamics Groupcla@dynamicsgroup.ch+41 22
308 6220 Office+41 79 476 26 87 Mobile
Media Contact U.S.:Marion
JanicRooneyPartners LLCmjanic@rooneyco.com+1 212-223-4017
CEO Office Contact:Shauna
DillonShauna.dillon@obseva.ch+41 22 552 1550
Investor Contact:Mario CorsoSenior
Director, Investor Relationsmario.corso@obseva.com+1 857 972 9347
Office+1 781 366 5726 Mobile